Minocycline for Chronic Autoimmune Uveitis

Overview

Autoimmune uveitis is one kind of non-infectious, sight-threatening, relapsing and severe ocular disease. Approximately 20%-25% autoimmune uveitis patients suffer from the dilemma of blindness for the chronic and persistent inflammatory state in the eyes, which results in continuous destroy in the structure of the eyes and gradually leads to irreversible damage on visual function. However, it shows limiting efficacy of current treatment including glucocorticoids, immunosuppressant and biologics for chronic autoimmune uveitis. Minocycline has been regarded to have anti-apoptosis and immunemodulatory function for decades and it has been illustrated to be beneficial in several neuro-degenerative and neuro-inflammatory diseases. This trial aims to investigate the efficacy and safety of minocycline for chronic autoimmune uveitis with retinal degenerative changes.

Full Title of Study: “The Efficacy and Safety of Minocycline for Chronic Autoimmune Uveitis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 31, 2025

Interventions

  • Drug: minocycline
    • minocycline capsule 100mg per day orally

Arms, Groups and Cohorts

  • Experimental: minocycline
    • minocycline capsule 100mg per day orally

Clinical Trial Outcome Measures

Primary Measures

  • Change of macular sensitivity
    • Time Frame: At 6 and 12 months
    • Change of macular sensitivity measured by MAIA
  • Change of BCVA
    • Time Frame: At 6 and 12 months
    • Change of BCVA measured by ETDRS
  • Change of Visual field
    • Time Frame: At 6 and 12 months
    • Change of Visual field measured by HVF 30-2 visual field testing
  • Changes in Implicit Time and Amplitude of Photopic and Scotopic Responses
    • Time Frame: At 6 and 12 months
    • Changes in Implicit Time and Amplitude of Photopic and Scotopic Responses measured by Electroretinogram (ERG) Testing

Secondary Measures

  • Change of macular vessel
    • Time Frame: At 6 and 12 months
    • Change of macular vessel measured by OCTA
  • Change of Contrast Sensitivity
    • Time Frame: At 6 and 12 months
    • Change of Contrast Sensitivity measured by F.A.C.T
  • Change of Color Visual
    • Time Frame: At 6 and 12 months
    • Change of Color Visual measured by FM100
  • Change of QoL questionaire
    • Time Frame: At 6 and 12 months
    • Change of QoL measured by VFI-25
  • Number of ocular and non-ocular adverse events Number of ocular and non-ocular adverse events Number of ocular and non-ocular adverse events Number of ocular and non-ocular adverse events Number of Ocular and Non-ocular Adverse Events
    • Time Frame: At 6 and 12 months

Participating in This Clinical Trial

Inclusion Criteria

  • Participant diagnosed of autoimmune diseases with visual function damage (decrease of BCVA, loss of retinal structure) – Participant aged from 18-60 years old. – Participant that signed the informed consent document and is able to complete the following visits. Exclusion Criteria:

  • Participant is allergy to minocycline or tetracyclines. – Participant has no contraindications of minocycline or tetracyclines. – Participant has an abnormal function of liver, heart, kidney and thyroid. – Participant is using glucocorticoids, immunosuppressants or biologics. – Female that is pregnant, breast-feeding or planning to become pregnant. – Participant that is currently using other medications for other diseases.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Sun Yat-sen University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Dan Liang, Dan Liang, PhD – Sun Yat-sen University
  • Overall Official(s)
    • Dan Liang, Principal Investigator, Zhongshan Ophthalmic Center, Sun Yat-sen University
  • Overall Contact(s)
    • Dan Liang, (86)-87330402, liangdan@gzzoc.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.